ArticleEndocrine, metabolic & immune disorders drug targets2026
Global Scientific Trends in the Use of Mesenchymal Stem Cells for the Treatment of Diabetes Mellitus from 2000 to 2023: A Bibliometric Study
Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetes mellitus is a chronic disease that seriously endangers human health, and mesenchymal stem cell (MSC) therapy is an emerging medical approach. Therefore, analyzing the effectiveness of MSCs in the literature is highly important for building relevant knowledge networks and promoting development in this field.
methodsThe Web of Science database was selected as the source of literature, and all the literature on MSCs in diabetes from January 1, 2000, to October 18, 2023, was selected. After screening, CiteSpace and VOSviewer were imported into bibliometric software to construct the knowledge visualization map. Journal analysis, author analysis, country/region analysis, reference analysis, and keyword analysis were performed.
resultsA total of 2912 articles and reviews were included. The number of articles on the use of MSCs for the treatment of diabetes is increasing annually. These publications originate mainly from 90 countries and 278 institutions, of which China and the United States were the top producers. We identified 15384 authors, with Liu Jiejie having the largest number of articles and Shapiro Amj being the most frequently co-cited. Stem Cell Research and Therapy was the most studied journal, and Diabetes was the most frequently cited journal. After analysis, the most common keywords were MSCs, diabetes mellitus, expression, transplantation, and differentiation.
conclusionsResearch into MSC-based interventions for diabetes is booming. In the future, cooperation and connections between various countries and institutions should be strengthened. MSC-induced differentiation into insulin-producing cells, MSCs homing in vivo, the therapeutic effect of MSCs on diabetic nephropathy, and the therapeutic effect of exosomes secreted by MSCs constitute the current research hotspots and development trends for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.